知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

79 条记录 (耗时 0.037 秒)

    Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor
    42.
    发明授权
    Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor 失效
    判断白血病，白血病前或白血病恶性血液病的诊断方法

    公开(公告)号：US07479371B2

    公开(公告)日：2009-01-20

    申请号：US10510627

    申请日：2003-04-09

    申请人： Kiyoshi Ando ,  Tomomitsu Hotta ,  Chie Ito ,  Hidenao Sato ,  Akiko Furuya ,  Kenya Shitara ,  Seiji Sugimoto ,  Hiroaki Kohno

    发明人： Kiyoshi Ando ,  Tomomitsu Hotta ,  Chie Ito ,  Hidenao Sato ,  Akiko Furuya ,  Kenya Shitara ,  Seiji Sugimoto ,  Hiroaki Kohno

    IPC分类号： G01N33/53 ,  C07K16/00

    CPC分类号： C07K16/22 ,  G01N33/57426 ,  G01N2333/475

    摘要： The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).

    摘要翻译： 本发明涉及白血病，白血病前或白血病恶性血液病诊断方法，白血病与白血病前白血病恶性血液疾病的鉴别方法，再生障碍性贫血与骨髓增生异常综合征的鉴别方法，延迟诊断方法 造血干细胞移植后造血干细胞的移植，以及诊断移植物抗宿主病的方法，每种方法包括量化干细胞生长因子（SCGF）。 本发明还可以提供用于诊断白血病，白血病前或白血病恶性血液病的药剂和用于诊断造血干细胞移植后的造血干细胞的延迟植入或用于诊断移植物与宿主的试剂的试剂 疾病（GVHD），各自含有与干细胞生长因子（SCGF）反应的抗体作为活性成分。

    Substance which inhibits binding of information transfer molecule for 1175-tyrosine phosphorylated KDR/Flk-1 and usages of the same
    44.
    发明申请
    Substance which inhibits binding of information transfer molecule for 1175-tyrosine phosphorylated KDR/Flk-1 and usages of the same 审中-公开
    抑制1175-酪氨酸磷酸化KDR / Flk-1的信息传递分子结合的物质及其用途

    公开(公告)号：US20050004003A1

    公开(公告)日：2005-01-06

    申请号：US10763276

    申请日：2004-01-26

    申请人： Masabumi Shibuya ,  Tomoko Takahashi ,  Akiko Furuya ,  Kenya Shitara

    发明人： Masabumi Shibuya ,  Tomoko Takahashi ,  Akiko Furuya ,  Kenya Shitara

    IPC分类号： C07K16/28 ,  C12Q1/48 ,  A61K38/17 ,  G01N33/574

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/34 ,  C12Q1/485 ,  G01N2500/04

    摘要： The present invention provides a substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/Flk-1 and inhibits cell growth by VEGF. Also, the present invention provides a method for inhibiting KDR/Flk-1 signal transduction, a method for inhibiting cell growth, a method for inhibiting angiogenesis, a method for screening a cell growth inhibitor, a method for screening an angiogenesis inhibitor, a method for screening a substance which inhibits KDR/Flk-1 signal transduction, a method for determining whether or not a tested substance can inhibit KDR/Flk-1 signal transduction, a method for detecting angiogenesis in tissue and a method for screening a substance which inhibits 1175-tyrosine phosphorylated KDR/Flk-1, in which each method comprises using the substance.

    摘要翻译： 本发明提供抑制信号转导分子与1175-酪氨酸磷酸化的KDR / Flk-1的结合并通过VEGF抑制细胞生长的物质。 此外，本发明提供抑制KDR / Flk-1信号转导的方法，抑制细胞生长的方法，抑制血管生成的方法，细胞生长抑制剂的筛选方法，血管生成抑制剂的筛选方法 用于筛选抑制KDR / Flk-1信号转导的物质，确定被检物质是否能抑制KDR / Flk-1信号转导的方法，检测组织中血管生成的方法和用于筛选抑制 1175-酪氨酸磷酸化KDR / Flk-1，其中每种方法包括使用该物质。

    Recombinant antibody composition
    46.
    发明授权
    Recombinant antibody composition 有权
    重组抗体组成

    公开(公告)号：US07923538B2

    公开(公告)日：2011-04-12

    申请号：US11491501

    申请日：2006-07-24

    申请人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

    发明人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

    IPC分类号： C12P21/08

    CPC分类号： C07K16/462 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734

    摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.

    摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

    Antibody Composition Specifically Binding to Ganglioside Gm
    47.
    发明申请
    Antibody Composition Specifically Binding to Ganglioside Gm 审中-公开
    特异性结合神经节苷脂Gm的抗体组成

    公开(公告)号：US20090028877A1

    公开(公告)日：2009-01-29

    申请号：US10575114

    申请日：2004-10-08

    申请人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Takabe ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara

    发明人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Takabe ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N5/06 ,  A61P31/00 ,  C12P21/04

    CPC分类号： C07K16/3084 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/732

    摘要： An anti-ganglioside GM2 antibody composition having enhanced effector function which is useful as a medicament has been desired. The present invention provides an antibody composition comprising an antibody molecule which specifically binds to ganglioside GM2 and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

    摘要翻译： 已经需要可用作药物的具有增强的效应子功能的抗神经节苷脂GM2抗体组合物。 本发明提供一种抗体组合物，其包含特异性结合神经节苷脂GM2并且在Fc区中具有复合型N-糖苷连接的糖链的抗体分子，其中复合型N-糖苷连接的糖链具有其中岩藻糖 在糖链的还原末端不与N-乙酰氨基葡萄糖结合; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

    CCR4-specific antibody composition
    48.
    发明申请
    CCR4-specific antibody composition 审中-公开
    CCR4特异性抗体组成

    公开(公告)号：US20050287138A1

    公开(公告)日：2005-12-29

    申请号：US10959310

    申请日：2004-10-07

    申请人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara

    发明人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2866 ,  C07K2317/41 ,  C07K2317/732

    摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

    摘要翻译： 本发明提供一种抗体组合物，其包含特异性结合人类CC趋化因子受体4（CCR4）的抗体分子，并且在Fc区具有复合型N-糖苷连接的糖链，其中复合型N-糖苷连接的糖链 在糖链的还原端具有岩藻糖不与N-乙酰葡糖胺结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。